Novo Nordisk to test diabetes tablet against Eli Lilly drug
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14230779.ece/ALTERNATES/schema-16_9/doc7ltgscypitf1fpp7cp5a.jpg)
In a new clinical study, Novo Nordisk is seeking to measure the efficacy and safety of a once-daily tablet version of semaglutide, comparing the drug to Eli Lilly’s daily tablet treatment, empagliflozin, according to a filing on database Clinical Trials.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.